France· FR:69994784
MYALEPTA 11,3 mg, poudre pour solution injectable
A metreleptin product containing métréleptine, registered in France by CHIESI FARMACEUTICI, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Metreleptin is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AA07 (metreleptin), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Metreleptin · ATC A16AA07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MÉTRÉLEPTINE
- Manufacturer
- CHIESI FARMACEUTICI
- Country
- France (FR)
- ATC code
- A16AA07
- ATC class
- Metreleptin
- Defined daily dose
- 5 mg, P
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip1334009301509311 flacon en verre de 5 mLEUR 1.8
- cip13340093015094830 flacons en verre de 5 mLEUR 50.64
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
193 interactions on record for metreleptin.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metreleptin · interactions on record
193 records
- 1 severe
- 188 moderate
- 4 minor
Most severe, free to view
- RolapitantA04AD14moderate
- NaloxegolA06AH03moderate
- Insulin (human)A10AB01moderate
- Insulin lisproA10AB04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Metreleptin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandMyalepta 11.3 mg powder for solution for injectionChiesi Farmaceutici S.p.A.
- NetherlandsMyalepta 11.3 mg poeder voor oplossing voor injectieChiesi Farmaceutici S.p.A.
- CzechiaMYALEPTAChiesi Farmaceutici S.p.A., Parma
- PolandMyaleptaChiesi Farmaceutici S.p.A.
- SwedenMyalepta 11,3 mg Pulver till injektionsvätska, lösningChiesi Farmaceutici S.p.A.
- BelgiumMyalepta 11.3 mgChiesi Farmaceutici
- FinlandMyaleptaChiesi Farmaceutici S.p.A.
- United KingdomMyalepta 11.3mg powder for solution for injection vialsChiesi Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Myalepta
- Liechtenstein · Myalepta
- Norway · Myalepta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/727e486d-31db-47fd-9080-4c90c2c03260 GET /v1/drugs/727e486d-31db-47fd-9080-4c90c2c03260?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69994784",
"date_amm": "2018-07-30",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/18/1276",
"substance": "MÉTRÉLEPTINE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about metreleptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.